The MCL Technology of BioMedCore, Inc.
The MCL Technology of BioMedCore, Inc.
Mannose Coated Liposome as DDS carrier and Vacccine Adjuvant.
What is the MCL(Mannose Coated Liposome)?
Characteristics of MCL
- MCL is a liposome coated with Mannose.
- MCL has a targeting ability to phagocytotic cells (Mφ,DC etc).
- Those API uptake MCL very quickly.
- MCL is able to induce Th1 cytokines( IL-12 etc.) from Mφ,DC etc.
- MCL encapsulated an antigen, is able to induce antigen-specific cytotoxic T cells in vivo and in vitro.
- BMC is doing R&D of MCL as a DDS carrier for chemotherapeutic agent, as a cancer and a protozoa vaccine, and as an in vitro adjuvant for detecting antigen specific CTL.
Evidences for MCL potential as Th1 Adjuvant
- Prevention and rejection of Leishmania infection in mice.
- Prevention and rejection of Toxoplasma infection in mice.
- Antigen specific IFN-γ induction from spleen cells of mice vaccinated with influenza HA/MCL.
- Antigen specific Th1 Cytokine(IFN-γ、IL-12 etc.) induction from PBMC in vivo and in vitro in mice, bovine or human.
- The strong efficacy of IL-12 induction by MCL is comparable with CpG-ODN.
- Induction of In vitro antigen specific CTL by using mice and human mononuclear cells
- Anti-cancer activity in vivo in mice.
- Anti-poline allergy activity in vivo in mice.
- All evidences above were induced by 10 to 10000 times lower dose of antigen.
Anti-Cancer effect of MCL vaccine
*Kojima N. et al. Oligomannose-coated liposome as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J Control Release. 129: 26-32 (2008)
MCL is the 1st Th1 vaccine Adjuvant sythesized!
Relevant material
Presentations>>